Nafoxidine hydrochloride
Nafoxidine hydrochloride (pronunciation: na-fox-i-dine hy-dro-chlor-ide) is a non-steroidal estrogen antagonist that was initially developed for the treatment of breast cancer. It is also known as U-11,000A.
Etymology
The term "Nafoxidine" is derived from the chemical nomenclature of the compound, specifically the "Na" for naphthalene, "fox" for phenoxy, and "idine" for the presence of an indole group. The "hydrochloride" refers to the presence of a hydrochloride salt, which enhances the solubility of the compound.
Pharmacology
Nafoxidine hydrochloride acts as an estrogen receptor antagonist, meaning it blocks the effects of estrogen in the body. This makes it potentially useful in conditions where estrogen is a contributing factor, such as certain types of breast cancer.
Clinical Use
While Nafoxidine hydrochloride was initially developed for the treatment of breast cancer, its clinical use has been limited due to side effects such as ocular toxicity. However, it has been used in research settings to study the role of estrogen in various biological processes.
Related Terms
External links
- Medical encyclopedia article on Nafoxidine hydrochloride
- Wikipedia's article - Nafoxidine hydrochloride
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski